For example, empagliflozin, a Na+-glucose cotransporter 2 (SGLT2) inhibitor, was reported to lower mortality, reduce RV systolic pressure, and attenuated maladaptive pulmonary remodeling in animal models, thereby preventing PAH progression (91). This evidence concerns the gene SLC5A2 and pulmonary arterial hypertension.